ANTENGENE CORP. DL-0001 (722) - Total Assets
Based on the latest financial reports, ANTENGENE CORP. DL-0001 (722) holds total assets worth €1.26 Billion EUR (≈ $1.47 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ANTENGENE CORP. DL-0001 - Total Assets Trend (2021–2025)
This chart illustrates how ANTENGENE CORP. DL-0001's total assets have evolved over time, based on quarterly financial data. Also see 722 market cap for the company's overall valuation and market capitalisation.
ANTENGENE CORP. DL-0001 - Asset Composition Analysis
Current Asset Composition (December 2025)
ANTENGENE CORP. DL-0001's total assets of €1.26 Billion consist of 62.3% current assets and 37.7% non-current assets. Review 722 liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 57.1% |
| Accounts Receivable | €27.47 Million | 2.2% |
| Inventory | €7.53 Million | 0.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.40 Million | 0.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how ANTENGENE CORP. DL-0001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ANTENGENE CORP. DL-0001 (722) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ANTENGENE CORP. DL-0001's current assets represent 62.3% of total assets in 2025, a decrease from 94.3% in 2021.
- Cash Position: Cash and equivalents constituted 57.1% of total assets in 2025, down from 88.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 2.2% of total assets.
ANTENGENE CORP. DL-0001 Competitors by Total Assets
Key competitors of ANTENGENE CORP. DL-0001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
ANTENGENE CORP. DL-0001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.97 | 6.53 | 5.72 |
| Quick Ratio | 2.94 | 6.44 | 5.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €519.20 Million | €809.83 Million | €918.24 Million |
ANTENGENE CORP. DL-0001 - Advanced Valuation Insights
This section examines the relationship between ANTENGENE CORP. DL-0001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.59 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | -6.5% |
| Total Assets | €1.26 Billion |
| Market Capitalization | $278.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values ANTENGENE CORP. DL-0001's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ANTENGENE CORP. DL-0001's assets decreased by 6.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ANTENGENE CORP. DL-0001 (2021–2025)
The table below shows the annual total assets of ANTENGENE CORP. DL-0001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.26 Billion ≈ $1.47 Billion |
-6.52% |
| 2024-12-31 | €1.34 Billion ≈ $1.57 Billion |
-16.92% |
| 2023-12-31 | €1.62 Billion ≈ $1.89 Billion |
-24.44% |
| 2022-12-31 | €2.14 Billion ≈ $2.50 Billion |
-16.24% |
| 2021-12-31 | €2.56 Billion ≈ $2.99 Billion |
-- |
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse lar… Read more